Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
  • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
  • C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
  • C08G73/0611—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only one nitrogen atom in the ring, e.g. polypyrroles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
  • C08G61/12—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule

Definitions

• amide is generally understood to refer to a group of formula C(0)NR a R b where R a and R b are hydrogen or an optionally substituted hydrocarbyl group.
• sulphonamide correspondingly relates to groups of formula S(0)2NR a R b .
• An electron withdrawing group or groups may be used in compounds of formula I to activate one or more of the double bonds in preparation for polymerisation. The nature of each electron withdrawing group will depend upon its position in relation to the double bond it is required to activate, as well as the nature of any other functional groups within the compound.
• R 6 will comprise a bridging group for example as is known in polymer chemistry. It may include straight or branched chain alkyl groups, optionally substituted or interposed with functional groups or siloxane groups such as alkyl siloxanes.
• the length of the bridging group will affect the properties of the polymeric material derived from the monomer. This can be used to design polymers with properties which are best suited to the application. For instance when the bridging group comprises relatively long chains, (for example with in excess of 6 repeat units, for example from 6-20 repeat units), the polymer will have pliable plastic properties. Alternatively, when the bridging group is relatively short, (e.g. less than 6 repeat units) the material will be more brittle.
• the poly (diallylamine) polymer used in the various aspects of the present invention may be a homopolymer, or a copolymer derived from a mixture of a monomer of formula I or la with another monomer. Many such other monomers are known in the art; they may themselves include diallylamine compounds.
• R 25 , R 26 , R 27 and R 28 are each independently selected from hydrogen or hydrocarbyl groups such as alkyl and in particular methyl; the compound optionally contains a metal ion such as magnesium or zinc, within the macrocyclic heterocyclic unit; and
• Particularly preferred polymers for use in the various aspects of the present invention are those derived from the monomers prepared in accordance with the experimental examples below.
• Compounds of formula I are suitably prepared by conventional methods, for example by reacting a compound of formula VIII:
• a further advantage is their versatility, allowing a wide range of desired physicochemical properties to be built into the polymers formed from them.
• either amorphous or ordered systems can be prepared depending upon the polymerisation conditions used. Copolymerisation can also be used to affect the physical properties of the end product.
• Systems can be prepared which mimic conventional polymers, or which involve donor/acceptor systems.
• the polymers can be produced in a range of physical forms, including films and coatings, using heat or radiation curing techniques if desired.
• Ir vmax (thin film): 3321 (s), 3086, 2934, 1620, 1551, 1420, 1358, 1234, 1136, 1060, 994, 927, 756, 665, 560 cm "1 .

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Polymers & Plastics (AREA)
• Nanotechnology (AREA)
• Medical Informatics (AREA)
• Crystallography & Structural Chemistry (AREA)
• Biophysics (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Surgery (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Gastroenterology & Hepatology (AREA)
• Diabetes (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=10864611

Family Applications (1)

Country Status (9)

Cited By (7)

Families Citing this family (33)

Family Cites Families (15)

• 1999
  • 1999-11-17 GB GBGB9927088.6A patent/GB9927088D0/en not_active Ceased
• 2000
  • 2000-11-10 EP EP00974674A patent/EP1265942B1/en not_active Expired - Lifetime
  • 2000-11-10 WO PCT/GB2000/004308 patent/WO2001036510A2/en not_active Ceased
  • 2000-11-10 AU AU12893/01A patent/AU772653B2/en not_active Ceased
  • 2000-11-10 DE DE60017805T patent/DE60017805T2/de not_active Expired - Lifetime
  • 2000-11-10 JP JP2001538997A patent/JP2003514935A/ja active Pending
  • 2000-11-10 AT AT00974674T patent/ATE287911T1/de not_active IP Right Cessation
  • 2000-11-10 US US10/130,246 patent/US7767229B1/en not_active Expired - Fee Related
  • 2000-11-10 CA CA002391539A patent/CA2391539C/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events